131 related articles for article (PubMed ID: 7583713)
1. The cell cycle as therapeutic target.
Broxmeyer H
Cancer Invest; 1995; 13(6):617-24. PubMed ID: 7583713
[TBL] [Abstract][Full Text] [Related]
2. The potential for the use of colony-stimulating factors in autologous bone marrow transplantation.
Peters WP
Recent Results Cancer Res; 1991; 121():182-8. PubMed ID: 1713337
[No Abstract] [Full Text] [Related]
3. Use and toxicity of the colony-stimulating factors.
Schriber JR; Negrin RS
Drug Saf; 1993 Jun; 8(6):457-68. PubMed ID: 7687134
[TBL] [Abstract][Full Text] [Related]
4. Circulating myeloid progenitor cell kinetics during hematologic recovery from chemotherapy and subsequent recombinant human granulocyte-macrophage colony-stimulating factor administration.
Ventura GJ; Reading CL; Hester JP; Vadhan-Raj S
Acta Haematol; 1990; 84(4):175-81. PubMed ID: 2125781
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
6. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
Yeung AW; Pang YK; Tsang YC; Wong SW
Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of cancer.
Fan D; O'Brian CA; Ioannides CG; Clyne RK
In Vivo; 1991; 5(6):571-7. PubMed ID: 1810441
[TBL] [Abstract][Full Text] [Related]
8. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
[TBL] [Abstract][Full Text] [Related]
9. Biological therapies in bone marrow transplantation.
Kochupillai V
Indian J Med Res; 1995 Apr; 101():129-33. PubMed ID: 7538493
[TBL] [Abstract][Full Text] [Related]
10. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
11. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
12. [Current status of the clinical application of hematopoietic growth factors in oncology].
Karthaus M; Ganser A
Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man.
Socinski MA; Cannistra SA; Elias A; Antman KH; Schnipper L; Griffin JD
Lancet; 1988 May; 1(8596):1194-8. PubMed ID: 2897009
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of synergy between granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in colony formation from human marrow cells in vitro.
Hara H; Namiki M
Exp Hematol; 1989 Aug; 17(7):816-21. PubMed ID: 2473914
[TBL] [Abstract][Full Text] [Related]
15. Colony-stimulating factors. Present status and future potential.
Fox RM
Pharmacoeconomics; 1994; 6 Suppl 2():1-8. PubMed ID: 10155591
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle status of erythroid (BFU-E) progenitor cells from the bone marrows of patients on a clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.
Broxmeyer HE; Cooper S; Vadhan-Raj S
Exp Hematol; 1989 Jun; 17(5):455-9. PubMed ID: 2653858
[TBL] [Abstract][Full Text] [Related]
17. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.
Broxmeyer HE; Cooper S; Williams DE; Hangoc G; Gutterman JU; Vadhan-Raj S
Exp Hematol; 1988 Aug; 16(7):594-602. PubMed ID: 3260558
[TBL] [Abstract][Full Text] [Related]
18. Haemopoietic progenitor and myeloid cell kinetics in humans treated with interleukin-3 and granulocyte/macrophage colony-stimulating factor in combination.
Lord BI; Testa NG; Bretti S; Chang J; Demuynck H; Coutinho L; de Campos E; Fitzsimmons L; Scarffe JH
Int J Cancer; 1994 Nov; 59(4):483-90. PubMed ID: 7960217
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P
Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
[TBL] [Abstract][Full Text] [Related]
20. [Methods of autologous peripheral blood stem cell (PBSC) mobilization in oncological and hematological patients].
Fregatova LM; Shavva SA; Platonova GG; Golovacheva AA; Afanas'ev BV
Vopr Onkol; 1999; 45(4):380-3. PubMed ID: 10532095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
